Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

Perkins Coie and Ashurst to merge into $2.7bn revenue firm
Careers
Perkins Coie and Ashurst to merge into $2.7bn revenue firm
The combination will create a firm with 3,000 lawyers across 52 offices—but a dive into its combined IP practice shows a heavy weighting in the US.   18 November 2025
Masimo bags $634m win over Apple—with latest watch under scrutiny
Americas
Masimo bags $634m win over Apple—with latest watch under scrutiny
A federal jury finds Apple infringed Masimo’s pulse oximetry patent, while the ITC has opened a new proceeding to review Apple's redesigned smartwatch.   17 November 2025
Too busy to save time? Why IP teams can’t afford to wait on AI
Europe
Too busy to save time? Why IP teams can’t afford to wait on AI
In-house counsel from AstraZeneca, BAT and Novartis say that investing in AI now will pay off in time saved, but warn that tools remain prone to ‘confident’ errors, writes Marisa Woutersen.   14 November 2025
Europe
7 in-house counsel tips for partnering with AI vendors in deals
Partnering with AI vendors can open doors for startups and small companies but it also brings serious risks. Experts at AI & IP Europe share key lessons on contracts, data ownership, ring-fencing, monitoring, and exit planning, as Marisa Woutersen reports.   11 November 2025
Pharma
Sun Pharma and BMS lead 2025 ANDA litigation
According to new research, generic and brand-name pharma companies are ramping up ANDA litigation with Sun Pharma and Bristol Myers Squibb leading the charge.   10 November 2025
Americas
The hidden code in life sciences deals
As IP plays a more important role in corporate valuations, acquirers are discovering that the biggest risks in life sciences deals aren’t always in the patents—they’re in the code, the algorithms, and the data. A panel at LSPN North America Fall shared why traditional due diligence is no longer enough.   27 October 2025
Americas
Why AI is changing the patent rules faster than anyone can keep up
A panel of experts at LSPN shared how AI is forcing companies to rethink everything from obviousness arguments to the choice between patents and trade secrets, and why the claims filed today may be invalid tomorrow.   24 October 2025
Americas
LSPN panel unpacks critical IP risks in deal-making
Experts at LSPN North America Fall explore the often-overlooked factors that can make or break transactions, from employee retention strategies to cross-border patent standards.   23 October 2025
Americas
Less is more: patent lawyers flip the script after Amgen
The Supreme Court’s 2023 Amgen ruling turned patent strategy upside down. Now lawyers are rethinking everything they thought they knew about protecting inventions. Marisa Woutersen reports from LSPN North America–Fall.   22 October 2025
Biotech
‘Doing more with less’: In-house counsel on budgets and strategy
Chuck Scholtz, head of IP at Verdiva Bio, shares the pressures of global filing strategies on tight budgets, why there’s no ‘right way’ to manage IP, and how to get the best results from external counsel relationships.   22 October 2025

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.